{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:17:05Z","timestamp":1780489025157,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.radonc.2022.109454","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T16:10:25Z","timestamp":1673453425000},"page":"109454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"180","author":[{"given":"Tairo","family":"Kashihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kae","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiteru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Itami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Igaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2022.109454_b0005","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2022.109454_b0010","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2022.109454_b0015","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jtho.2019.10.002","article-title":"Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC","volume":"15","author":"Gray","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2022.109454_b0020","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.109454_b0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2020.10.008","article-title":"Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study","volume":"142","author":"Desilets","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2022.109454_b0030","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/1759-7714.14452","article-title":"Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone","volume":"13","author":"Saad","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.radonc.2022.109454_b0035","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ijrobp.2021.12.150","article-title":"Real-World Safety and Efficacy of Consolidation Durvalumab After Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis","volume":"112","author":"Wang","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.109454_b0040","doi-asserted-by":"crossref","first-page":"e2224478","DOI":"10.1001\/jamanetworkopen.2022.24478","article-title":"Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer","volume":"5","author":"Pichert","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.radonc.2022.109454_b0045","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2020.10.006","article-title":"Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)","volume":"150","author":"Faehling","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2022.109454_b0050","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ijrobp.2022.03.015","article-title":"Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab","volume":"113","author":"Bryant","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.109454_b0055","article-title":"A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer","volume":"28","author":"Bruni","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2022.109454_b0060","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s12885-022-09354-1","article-title":"Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice","volume":"22","author":"Yamamoto","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2022.109454_b0065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2020.05.035","article-title":"Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"146","author":"Jung","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2022.109454_b0070","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.21037\/tlcr-21-249","article-title":"Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab","volume":"10","author":"Jazieh","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.radonc.2022.109454_b0075","doi-asserted-by":"crossref","first-page":"e2215589","DOI":"10.1001\/jamanetworkopen.2022.15589","article-title":"Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab","volume":"5","author":"Liu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.radonc.2022.109454_b0080","doi-asserted-by":"crossref","unstructured":"McCall NS, McGinnis HS, Janopaul-Naylor JR, et al. Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era. Radiother Oncol. 2022 Jul 20;174:133-140.","DOI":"10.1016\/j.radonc.2022.07.015"},{"key":"10.1016\/j.radonc.2022.109454_b0085","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1111\/1759-7714.13631","article-title":"Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review","volume":"11","author":"Zhang","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.radonc.2022.109454_b0090","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/1759-7714.13764","article-title":"Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone","volume":"12","author":"Abe","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.radonc.2022.109454_b0095","article-title":"Usefulness of Simple Original Interstitial Lung Abnormality Scores for Predicting Radiation Pneumonitis Requiring Steroidal Treatment After Definitive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer","volume":"6","author":"Kashihara","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.109454_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","article-title":"ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer","volume":"127","author":"Nestle","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.109454_b0105","article-title":"Initial Experience of Intentional Internal High-Dose Policy Volumetric Modulated Arc Therapy of Neck Lymph Node Metastases \u2265 2 cm in Patients With Head and Neck Squamous Cell Carcinoma","volume":"27","author":"Kashihara","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2022.109454_b0110","doi-asserted-by":"crossref","first-page":"e20860","DOI":"10.1097\/MD.0000000000020860","article-title":"A case report of a patient with bulky uterine cervical neoplasm who achieved complete response with \u201cintentional internal high-dose policy\u201d high-dose-rate interstitial brachytherapy","volume":"99","author":"Kashihara","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.radonc.2022.109454_b0115","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.radonc.2022.109454_b0120","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1080\/0284186X.2020.1781249","article-title":"Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score \u226550% treated with front-line pembrolizumab","volume":"59","author":"Friedlaender","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2022.109454_b0125","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1002\/cncr.32782","article-title":"Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors","volume":"126","author":"Petrillo","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2022.109454_b0130","doi-asserted-by":"crossref","first-page":"e2037120","DOI":"10.1001\/jamanetworkopen.2020.37120","article-title":"Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy","volume":"4","author":"Sehgal","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.radonc.2022.109454_b0135","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/cncr.32645","article-title":"Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors","volume":"126","author":"Khaki","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2022.109454_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1148\/radiol.2018181684","article-title":"Interstitial Lung Abnormality: Recognition and Perspectives","volume":"291","author":"Hatabu","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.radonc.2022.109454_b0145","first-page":"726","article-title":"Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet","volume":"8","author":"Hatabu","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.radonc.2022.109454_b0150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13014-021-01979-z","article-title":"Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer","volume":"17","author":"Mayahara","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.109454_b0155","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1269\/jrr.110142","article-title":"Association of computed tomography-detected pulmonary interstitial changes with severe radiation pneumonitis for patients treated with thoracic radiotherapy","volume":"53","author":"Sanuki","year":"2012","journal-title":"J Radiat Res"},{"key":"10.1016\/j.radonc.2022.109454_b0160","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10637-021-01191-6","article-title":"Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer","volume":"40","author":"Nishimura","year":"2022","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.radonc.2022.109454_b0165","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41416-019-0541-3","article-title":"Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer","volume":"121","author":"Yoneda","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2022.109454_b0170","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/1759-7714.14484","article-title":"Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy","volume":"13","author":"Araki","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.radonc.2022.109454_b0175","doi-asserted-by":"crossref","first-page":"886","DOI":"10.21037\/tlcr.2019.11.16","article-title":"Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)","volume":"8","author":"Mandaliya","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.radonc.2022.109454_b0180","doi-asserted-by":"crossref","first-page":"e18607","DOI":"10.1097\/MD.0000000000018607","article-title":"Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer","volume":"99","author":"Huang","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.radonc.2022.109454_b0185","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022046060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022046060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:28:18Z","timestamp":1718238498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814022046060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":37,"alternative-id":["S0167814022046060"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2022.109454","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2022.109454","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109454"}}